Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Income Statement

Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Revenue" came in at 4,777,450 million JPY. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of JPY.

Tick rows to compare them in a chart (up to 4)

Income Statement TAK
Line item	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	923,132	963,480	1,005,060	1,046,081	1,086,431	1,122,960	1,212,207	1,305,167	1,374,802	1,538,336	1,465,965	1,419,385	1,508,932	1,557,267	1,691,685	1,777,824	1,807,378	1,732,051	1,770,531	2,097,224	3,291,188	3,197,812	3,569,006	4,027,478	4,263,762	4,581,551	4,777,450
Cost of Revenue	432,333	384,013	337,854	300,344	269,395	279,179	282,102	279,662	278,631	289,543	285,064	317,582	433,194	447,628	490,263	520,990	535,405	558,755	495,921	659,690	1,089,764	994,308	1,106,846	1,244,072	1,431,505	1,580,217	2,338,119
Gross Profit	490,799	579,467	667,206	745,737	817,036	843,781	930,105	1,025,505	1,096,171	1,248,793	1,180,901	1,101,803	1,075,738	1,109,639	1,201,422	1,256,834	1,271,973	1,173,296	1,274,610	1,437,534	2,201,424	2,203,504	2,462,160	2,783,406	2,832,257	3,001,334	2,439,332
Research & Development	–	–	–	–	–	–	–	–	–	–	–	–	–	324,292	341,560	382,096	345,927	312,303	325,441	368,298	492,381	455,833	526,087	633,325	729,924	730,227	716,688
Selling, General & Administrative	319,356	–	385,963	–	–	–	–	–	–	834,229	666,683	640,197	810,711	811,618	450,957	499,401	650,773	619,061	628,106	717,599	964,737	875,663	886,361	997,309	1,053,819	1,104,766	1,084,215
Total Operating Expenses	319,356	353,365	385,963	435,051	445,403	458,503	527,296	567,005	673,048	942,325	760,690	734,719	810,711	987,134	1,062,149	1,386,088	1,141,145	1,017,429	1,032,821	1,277,169	2,101,016	1,694,235	2,001,315	2,292,900	2,618,182	2,658,748	1,866,289
Operating Income	171,443	226,102	281,243	310,686	371,633	385,278	402,809	458,500	423,123	306,468	420,211	367,084	265,027	122,505	139,274	-129,254	130,828	155,867	241,789	204,969	100,408	509,269	460,844	490,505	214,075	342,586	573,042
Interest Expense	1,194	1,020	759	420	359	334	365	247	333	1,621	1,429	1,335	1,883	3,323	30,720	32,878	31,931	23,250	31,928	48,158	1,459	130,806	122,432	116,973	1,062	137,311	379,136
Pre-Tax Income	202,764	263,076	373,427	431,898	446,144	441,102	517,957	625,379	576,842	398,546	415,829	371,572	252,478	129,707	158,851	-145,437	120,539	143,346	217,205	94,896	-60,754	366,235	302,571	375,090	52,791	175,084	275,880
Income Tax Expense	81,446	114,148	134,892	157,485	157,911	160,231	201,361	285,844	218,766	161,351	115,668	121,326	125,208	-3,880	49,292	-2,403	37,059	27,833	30,497	-14,118	-105,044	-9,936	72,405	58,052	-91,406	66,941	72,274
Net Income	119,625	146,855	235,656	271,762	285,264	277,438	313,249	335,805	355,454	234,385	297,744	247,868	124,162	131,244	106,658	-145,775	80,166	114,940	186,886	109,126	44,241	376,005	230,059	317,017	144,067	107,928	203,327
EBITDA	237,322	297,701	402,616	462,280	474,586	472,662	547,050	654,446	608,865	518,248	532,083	479,629	404,555	351,176	368,181	57,287	349,851	296,876	359,956	464,216	671,905	983,718	1,183,213	1,284,067	1,143,936	1,210,512	1,419,633

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings